Pursuant to Regulation 30 of the SEBI Listing Regulations, Lincoln Pharmaceuticals has informed that the new manufacturing facility of the Company located at Block No-176, Trimul Estate, Khatraj, Dis-Gandhinagar, Gujarat has successfully completed its trial run. Further, the facility is expected to commence the commercial production of APIs (Active Pharmaceutical Ingredients) within 1 to 2 years depending upon additional product permission received from Food & Drugs Control Administration. Disclosures required under Regulation 30 read with Schedule III of the SEBI Listing Regulations read along with SEBI Master Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated 11th November, 2024, SEBI Circular No. SEBI/HO/CFD/CFDPoD-2/P/CIR/2025/25 dated 25th February, 2025 (SEBI Circulars) read with Industry Standards Note on Regulation 30 of the SEBI Listing Regulations, is enclosed as ‘Form A’.
The above information is a part of company’s filings submitted to BSE.
